Influenza is a viral pandemic that affects millions of people worldwide. Seasonal variations due to genetic shuffling and antigenic drifts in the influenza viruses have necessitated continual updating of therapeutics.
Introduction
Despite years of research into inuenza, this long-known, highly contagious disease continues to take its toll on millions of people of all ages every year. A substantial proportion of the affected suffer the life-threatening variant resulting in a typical mortality of 250 000-500 000 per u season. 1, 2 The major factors impeding the development of efficient antivirals are: (1) the growing resistance of current inuenza strains against existing drugs; and (2) the continued evolution of the inuenza virus. 2, 3 Both of these generate strains with varying virulence and transmissibility each season. The key molecular event responsible for this is the genetic reassortment or gene shuffling that occurs in the course of a viral infection. During viral RNA replication in a host cell infected with multiple inuenza strains, segments of the viral RNA genome get shuffled randomly (genome reassortment). The newly assembled viral progeny may contain mutations that empower the new strains with properties like drug-resistance or evasion of pre-existing host immunity (cf. 'antigenic dri'). For example, the 2009 H1N1 pandemic strain (H1N1pdm09 S-OIV), which is a reassortant progeny of the avian, human, and swine inuenza viruses, 4 was found to be resistant to oseltamivir [Tamiu] in patients with prior exposure to the drug due to accumulation of mutations in the drug-binding site. 5, 6 Therefore, there is a crucial need to develop antivirals that can surpass the seasonal variation and drug-resistance issues in order to be efficient. Current inuenza drugs are comprised of neuraminidase inhibitors (oseltamivir/Tamiu, zanamivir/Relenza, peramivir and laninamivir) and adamantine derivatives (amantadine and rimantadine) that exclusively target the viral envelope and membrane proteins, neuraminidase (NA) and M2 hydrogen ion channel, respectively. 2, 3 Both these proteins are highly prone to mutations and thus develop drug resistance rapidly. 2, 3 Furthermore, the only approved prophylactic measure currently available employs immunotherapy using neutralising antibodies that target the mutation-prone envelope protein haemagglutinin (HA). 7 As a result of seasonal variation in the HA protein, these vaccines are continually reformulated and annually re-administered to the public at a great expense. Even then, these vaccines do not protect against novel 'antigenic-shi' subtypes that have evolved with changes in the entire HA gene, and thus posing pandemic risks such as the H3 subtype in the 1968 pandemic.
NP is a biologically signicant multi-functional protein critical for viral RNA replication, genome trafficking and viral assembly. 8 More importantly, NP is serotypically distinct 8 and extensively conserved among Inuenza A strains. [8] [9] [10] The evolution rate of the inuenza viral genes is estimated to be 2 Â 10 6 higher than that of eukaryotic gene equivalents, 11 with an average nucleotide substitution rate of up to 4.6 Â 10 À3 substitutions per site per year in HA genes, 12 and up to 4.4 Â 10 À3 substitutions per site per year in NA genes. 13, 14 In comparison, the NP gene has only 2.4 Â 10 À3 substitutions per site per year according to a recent large-scale analysis of >5000 NP nucleotide sequences. 15 At the protein level, only 30.1% amino acid residues were found to be polymorphic in NP, out of the 2500 Inuenza A NP sequences analysed. 10 Furthermore, NP is abundantly expressed during infection 16 and readily detected as early as 2 days post-infection in mouse models. 17 Recently, several groups have investigated the potential of NP as an antiviral target and have identied a few prospective drugsi.e. nucleozin and its analoguesthat cause aggregation of NP, thereby blocking its functions, such as viral genome trafficking 18 and replication. [19] [20] [21] [22] These compounds were shown to be effective against a broad range of Inuenza A viral strains including H1N1, H3N2, and H5N1 in cell culture experiments and against highly pathogenic avian inuenza (HPAI) H5N1 in mouse models. [19] [20] [21] [22] However, in view of the evolution of strain variants and drug resistance, there is also a need to identify NP mutants that are likely to be resistant to these drugs.
Owing to its ability to confer heterosubtypic immunity, anti-NP antibodies have recently received increasing emphasis in developing a universal vaccine. Thus far, vaccinations with puried NP or DNA vectors have been the main mode of eliciting the antibody response. [23] [24] [25] [26] The potential of non-neutralising anti-NP antibodies that are elicited by natural infection and these vaccinations are shown to play an important role in conferring heterosubtypic immunity. 27 Furthermore, passive administration of anti-NP antibodies to naive mice has not only been shown to convey protection against infection, 27 but also rescues the reduced heterosubtypic immunity up to 1.5 years post-infection. 28 Nevertheless, it was noted that mice required an injection of puried anti-NP IgG to a nal serum titer of 10 5 in order to reduce the viral load. 17 Large-scale production of anti-NP antibodies for passive administration would thus be an ideal strategy to boost antibody titers.
In birds, the circulating serum antibodies are transferred to egg yolks as a means of conferring passive immunity to the embryos. 29 Chicken immunoglobulin (IgY) is very similar to mammalian IgG and highly stable. [30] [31] [32] [33] [34] IgY has been used successfully for therapeutic and prophylactic administration in humans and animals with good tolerance and no complement activation. 35, 36 Passive administration of IgY can be accomplished via oral or intranasal routes. 37, 38 In recent years, this non-invasive technology is being increasingly utilised as a cheap source of antibody production owing to its high and longlasting yields (up to 2 years). 39 A typical egg laying hen can yield 1500 mg IgY per month, of which 2-10% is antigen-specic IgY. 40 As IgYs are the only antibody isotype present in the egg yolk, extraction is fast and simple. Compared to other sources of antibody production, hyperimmunised chickens oen produce antibodies against highly conserved epitopes that may not normally be recognised by mammalian immune systems; 37 thereby increasing the chances of obtaining a higher affinity antibody against the desired antigen. Passive administration of polyclonal IgY generated against H5N1 and H1N1 viruses has previously been shown to be efficacious in conferring protection against homologous and heterologous lethal challenge infection in mice. 37, 41 A further study has demonstrated the in vitro antiviral activity of anti-Inuenza B IgY. 42 Here, we report for the rst time the production of a highly specic polyclonal anti-NP IgY from chicken egg yolks that has potential for immunotherapy and the development of a simple and fast aggregation-based in vitro assay ( Fig. 1 ) capable of identifying NP-targeting biologics and chemicals with a similar mode of action to that of nucleozin, i.e. specic aggregation of NP. [19] [20] [21] [22] Materials and methods
Reagents
The H1N1 NP puried from A/Beijing/262/95 H1N1 inuenza virus infected chicken eggs was obtained from Virusys Corporation, Taneytown, MD. Nucleozin was obtained from Chem-Bridge Corporation, San Diego, CA.
Cloning
Escherichia coli strain DH12S was used routinely as the host strain during construction of vectors. The NP used in this study was originally derived from pGEM-NP containing the NP sequence of A/Viet Nam/1203/2004 (H5N1) (Gen-Bank:AAW80720). 43 To generate pET-His 6 -NP (pHA228), the pET-His 6 -NP-GFP 43 was digested with NheI, end-lled and re-ligated to introduce a stop codon at the end of the NP open reading frame, thereby eliminating the C-terminal GFP coding sequence. The vector pET16bD2 encoding the domain III of the Dengue (DENV-2 TSV01) virus envelope protein (EDIII) with an N-terminal 6-His-tag 44,45 was a kind gi from A/Prof. Subhash Vasudevan (Duke-NUS, Singapore).
Protein expression and purication
Vectors were transformed into the E. coli strain BL21(DE3)RIPL (Stratagene) for protein expression. NP-GFP 43 and NP were expressed and puried using Pronity IMAC Ni-charged resin (Bio-Rad) as described previously. 46 Briey, cultures were grown at 37 C in OvernightExpress Instant TB Medium (Novagen) until an OD 600 of 0.5 was reached, followed by incubation at 16 C with vigorous shaking for 3 days. Harvested cells were resuspended in lysis buffer 1 (45 mM Na 2 HPO 4 , 5 mM NaH 2 PO 4 (pH 7.8), 300 mM NaCl, 10% (v/v) glycerol, 2 mM b-mercaptoethanol, 10 mM imidazole), lysed at 10 000 psi using a French pressure cell and centrifuged at 40 000g for 30 min at 4 C. Eluted fractions containing NP and NP-GFP in elution buffer 1 (lysis buffer 1 + 200 mM imidazole) were precipitated at 4 C with 0.3 and 0.5 g ml À1 (NH 4 ) 2 SO 4 , respectively and centrifuged at 18 000g for 30 min at 4 C. GFP, 46 NP and NP-GFP pellets were resuspended and stored in buffer A (45 mM Na 2 HPO 4 , 5 mM NaH 2 PO 4 (pH 7.8), 300 mM NaCl, 10% (v/v) glycerol) and buffer B (45 mM Na 2 HPO 4 , 5 mM NaH 2 PO 4 (pH 7.8), 10% (v/v) glycerol, 2 mM b-mercaptoethanol), respectively. GFP was stored in buffer B. For aggregation studies with nucleozin, the NP-GFP, GFP and NP proteins were dialysed with buffer C (50 mM Tris-Cl (pH 7.5), 100 mM NaCl) consistent with previous studies. 19, 47 For the control viral protein EDIII: following transformation with pET16bD2, E. coli BL21(DE3)RIPL cells were grown at 16 C with vigorous shaking (200 rpm) in OvernightExpress Instant TB Medium (Novagen) for 4 days. Cells were lysed and centrifuged as above. The pellet containing EDIII was refolded from inclusion bodies using a modication of a previously described protocol. 44 Briey, the pellet was washed in 1 M urea and 2% Triton X-100, centrifuged at 40 000g for 30 min at 4 C, and solubilised in lysis buffer 2 (18 mM Na 2 HPO 4 , 2 mM NaH 2 PO 4 (pH 7.8), 300 mM NaCl, 8 M urea, 10 mM b-mercaptoethanol, nal pH 8.25) overnight. The soluble fraction was loaded onto a Pronity IMAC Ni-charged resin (Bio-Rad) pre-equilibrated with the same buffer. Proteins were eluted with elution buffer 2 (lysis buffer 2 + 200 mM imidazole) and refolded by dialysis (10 000 MWCO SnakeSkinÒ pleated dialysis tubing, regenerated-cellulose, Pierce) against MilliQ water (1 l Â 2) for 28 h at 4 C.
All puried proteins were assessed for purity by SDS-PAGE and quantied by standard Bradford assay (Sigma).
Production and purication of IgY
Female leghorn chickens Gallus gallus were repeatedly immunised (i.e. 6 boosters following primary) via intramuscular injections of 100 mg puried NP mixed 1 : 1 (v/v) with adjuvant (Emulsigen, Intervet). As a negative control, another set of chickens was repeatedly immunised with puried EDIII mixed with adjuvant. Eggs were collected 3-4 weeks post-immunisation and the IgY was extracted and puried from the yolks using modied PEG precipitation and dialysis. 48 Briey, the yolk was separated from the egg whites and the IgYs in the yolk were puried by a 2-step precipitation with PEG 6000 at a nal concentration of 12% (w/v). Following precipitation, the IgY extract was dialysed in PBS. IgYs were assessed for purity by SDS-PAGE (reducing and non-reducing) and quantied by standard Bradford assay (Sigma).
Immunoblotting
Samples of puried recombinant proteins separated by SDS-PAGE were transferred onto PVDF membrane (BioRad) pre-wet with methanol for 30 s, via semi-dry electroblotting at 15 V for 25 min in transfer buffer (0.19 M glycine, 25 mM Tris). Following blocking with 5% skim milk in PBS buffer (10 mM Na 2 HPO 4 , 1.5 mM NaH 2 PO 4 (pH 7.4), 137 mM NaCl, 2.7 mM KCl) at RT for 1 h, blots were probed with diluted (1 : 1000 in 1% skim milk in PBS buffer) anti-NP or anti-EDIII IgYs at RT for 1 h. Aer washing three times for 5 min with PBS-T buffer (PBS + 0.05% (v/v) Tween-20), blots were probed with peroxidaseconjugated anti-IgY (Jackson Immunoresearch Laboratories Inc.) diluted 1 : 5000 in 1% skim milk in PBS buffer for 1 h at RT. PVDF membranes were washed again three times with PBS-T buffer and developed with 5 ml SIGMAFASTÔ 3,3 0 -diaminobenzidine/H 2 O 2 solution to visualise immunoreactive bands.
NP-GFP aggregation assay with nucleozin
For the aggregation reactions, 9 volumes of NP, NP-GFP and GFP proteins in buffer C, were treated individually or as mixtures, with 1 volume of increasing concentrations of nucleozin in DMSO and incubated at room temperature (RT, 25 C) for 1 h. Reactions were performed in a total reaction volume of 75 ml and at a nal concentration of 4 mM NP. Aer incubation, reactions were centrifuged at 15 000g for 30 min at 4 C in a bench-top centrifuge (Eppendorf 5810R, rotor: F45-48-PCR). Quantication was carried out using densitometric analysis and/or by measuring the uorescence in the supernatant as previously described. 43, 49 Briey, for densitometric analysis, 10 ml of supernatant was subjected to SDS-PAGE followed by Coomassie blue staining. Protein bands were integrated using ImageJ soware (http:// rsbwed.nih.gov/ij/) and normalised against bands obtained for control (untreated) reactions as previously described. 49 For uorescence measurements, 50 ml supernatants were transferred to a black 96-well plate (Nunclon) and read in a uorescence plate reader (Victor V Wallace Perkin-Elmer) with 40 nm band-width lters at excitation and emission settings of 355 nm and 535 nm, respectively.
Soluble fractions (F sol ) were calculated by dividing the uorescence value obtained for a reaction (+nucleozin) with the uorescence value of a control reaction (Ànucleozin).
NP-GFP agglutination assay with IgY
NP-GFP was mixed 1 : 1 (v/v) with varying concentrations of IgY (in PBS) in 30-90 ml reaction volumes and incubated at RT for 30 min. The nal concentration of NP-GFP was 0.5 mM in the reaction volume, except for the concentration-dependent agglutination where varying concentrations of NP-GFP were used as specied ( Fig. 3E ). Aer incubation, reactions were centrifuged at 15 000g for 30 min at 4 C. The pellets were analysed by SDS-PAGE and silver staining. 50 Densitometric quantication of the stained protein bands and the uorescence in the supernatants were determined as above.
Results

Principle of NP-GFP aggregation assay
We have previously developed an assay called GFP-Basta to measure the ligand-induced thermal stabilization of a protein of interest. 49 We applied this assay on NP-GFP and identied an NP-binding ssDNA that was further applied to develop an ultrasensitive immuno-PCR assay. 43 A further assay based on differential scanning uorimetry of GFP-tagged proteins 51 was recently applied to NP-GFP, but the intrinsic high stability of NP was a limiting factor for this assay and could therefore not be applied for high-throughput screening of stabilizing compounds. Building on these previous observations and limitations, a new NP-GFP aggregation assay was developed to allow identication of NP-targeting anti-inuenza agents with similar modes of action to that of nucleozin, i.e. irreversible and specic aggregation of NP. [19] [20] [21] [22] The NP-GFP aggregation assay uses GFP tethered to the C-terminus of NP as a quantitative reporter of NP aggregation and is applied for the detection of chemically-triggered NP aggregation at room temperature (Fig. 1) . Following treatment of NP-GFP with molecules triggering aggregation of NP in a 96-well PCR plate, the reaction is centrifuged and the soluble fraction (F sol ) of NP can be directly determined from the fraction of residual uorescence corresponding to the fraction of soluble NP-GFP in the supernatant. The quantication can be performed by uorimetric analysis using a uorescence plate reader or by SDS-PAGE and densitometric analysis of protein bands.
Validation of NP-GFP aggregation assay with nucleozin
Nucleozin inhibits NP functionality by aggregating NP molecules into high-order oligomers. 19, 21 To validate the utility of NP-GFP for developing an aggregation-based drug screening assay, we tested and compared the effect of nucleozin on NP-GFP, GFP and NP. Nucleozin and protein samples were mixed and incubated at room temperature for 1 hour. Thereaer, the protein aggregates were removed by centrifugation and the soluble fractions of each protein was quantitated by SDS-PAGE and densitometry ( Fig. 2A) . In order to eliminate the effect of buffer variation and allow direct comparison of specic druginduced effects on the different proteins in identical conditions, we rst treated a mixture of GFP (4 mM), NP (2 mM) and NP-GFP (2 mM) with increasing concentrations of nucleozin (2, 4, 20 and 40 mM) for 1 h. Comparison of the aggregation curve of NP with that of NP-GFP immediately suggested that nucleozin aggregates NP slightly more efficiently than NP-GFP (Fig. 2B) . Nevertheless, the data also demonstrated that a similar concentration-dependent aggregation was triggered by nucleozin in both NP and NP-GFP, while GFP remained unaffected across all nucleozin concentrations (Fig. 2B ). An unidentied protein (CP) that co-puried with NP was also observed to be Table S2 in ESI †).
unaffected by nucleozin and hence was used as a control in the densitometric method ( Fig. 2A) . A second experiment was performed where NP (4 mM) and NP-GFP (4 mM) were analysed separately in the presence of increasing nucleozin concentrations under similar conditions (Fig. 2C ). Here again, we observed that the aggregation of NP-GFP is slightly inhibited compared to NP (cf. Fig. 2B and D ). Yet NP-GFP was consistently aggregated by nucleozin and can therefore be applied as a reporter for NP aggregation. The F sol of NP-GFP for each nucleozin concentration was quantied by uorimetry and reected the densitometric data (Fig. 2D) . A slightly higher background was observed with the uorimetric method but saturation curves were otherwise identical. The data suggests that the aggregation of NP in the fusion protein is slightly inhibited by the presence of GFP, probably through either a kinetic and/or steric effect. The absence of any ligand-induced effect on GFP or control indicated the specicity and sensitivity of the assay with partially puried or mixtures of proteins. Together, these results validate the use of NP-GFP aggregation based assay for drug screening and resistance proling studies. Finally, a kinetic evaluation of the assay demonstrated that 1 h incubation with nucleozin was optimal for uorimetric quantitation of aggregation and assay reproducibility but that longer incubation times could be used if needed (Fig. S1, ESI †) .
Validation of NP-GFP aggregation assay with anti-NP chicken antibody
In a next step, we investigated the potential of the NP-GFP aggregation assay to be applied for the screening of biologics promoting aggregation of NP, such as NP-specic antibodies. Recombinant NP expressed in E. coli has previously been shown to efficiently elicit cross-protective immunity in mice. 52 Here, NP was expressed in E. coli and puried by Ni-affinity chromatography. The puried proteins were then used to immunise chickens. The anti-NP chicken IgYs were puried from the egg yolks of immunised chickens (Fig. 3A) and analysed by immunoblotting (Fig. 3B) . The anti-NP IgY fraction obtained showed a strong and specic reactivity against our recombinant H5N1 NP as well as a viral H1N1 NP. Additionally, the Dengue virus envelope protein (EDIII) was produced to serve as a negative control and for the production of a non-specic IgY fraction that was used as a negative control. No reactivity was observed with the negative control (EDIII, 15 kDa). The negative control anti-EDIII IgY showed no reactivity against our recombinant H5N1 NP.
Next, we investigated the effect of increasing concentrations (0.625-30 mM) of IgY on NP-GFP (0.5 mM). Aer 30 min incubation at room temperature, the extent of NP-GFP agglutination was determined aer centrifugation and SDS-PAGE. Agglutination of NP-GFP was observed at concentrations starting from 5 mM anti-NP IgY, while no agglutination was caused by anti-EDIII IgY at any tested concentration (Fig. 3C) . Qualitative assessment of the protein pellets aer centrifugation and UV transillumination conrmed these ndings (data not shown). The faint bands observed in the absence of IgY represent background levels of NP-GFP aggregation (Fig. 3C) .
Fluorimetric quantitation of the reaction supernatants further conrmed these observations (Fig. 3D) .
Antibody-mediated agglutination is dependent on both the concentrations of antibody and antigen, i.e. NP-GFP. We investigated the effect of increasing concentrations of NP-GFP against a dilution series of IgY to demonstrate that antibodymediated agglutination was indeed responsible for aggregation of NP-GFP (Fig. 3E ). As expected, when higher concentrations of NP-GFP were used a proportionally higher concentration of NP-specic IgY was needed to induce NP-GFP agglutination. Together, these results validate the use of the NP-GFP aggregation assay for the quantitative detection of NP-specic antibodies.
Discussion
Nucleozin and its analogues are a new class of promising inuenza antivirals. They show potent antiviral activity in cell culture and mouse model experiments due to their ability to aggregate NP. In spite of the conserved nature of NP, some of these aggregating compounds were inactive against NP variants harbouring particular mutations. [19] [20] [21] [22] The simplicity and speed of our NP-GFP aggregation assay offers the much needed technology to fast-track the screening and development of new compounds with similar modes of action. Our NP-GFP aggregation assay is an attractive alternative to the recently developed uorescence quenching assay 47 as it can be applied with partially puried proteins, eliminating the need for elaborate protein purication. The GFP domain was not subject to aggregation which demonstrates that nucleozin is very specic. GFP can therefore be used as a control protein, i.e. if GFP aggregation is induced by a compound it would be classied as non-specic. The variant of GFP (GFPuv) used in this study is thermostable in a pH range between 5 and 12. 53 This broad pH range can be useful to study the effect of pH on ligand-induced aggregation of NP.
We anticipate that the assay could be translated into a highthroughput format through the replacement of the centrifugation step by a ltration step and the use of appropriate liquid handling robotics. Moreover, both induction and inhibition of protein aggregation can be monitored using this assay. Further applications of this assay format could therefore be extended to study aggregation-prone proteins such as prions, Alzheimer's Ab and tau. Limiting protein aggregation is a key issue encountered across all stages of the biopharmaceutical formulation and drug development process. This assay could be applied to monitor buffer-induced and undesirable protein aggregation.
The newly developed anti-NP IgY demonstrated specic affinities against both recombinant H5N1 and viral H1N1 NP. This cost-effective, high-yield source of anti-NP IgY has potential for large-scale production and development of therapeutic antibodies. The NP-GFP agglutination induced by the new anti-NP IgY was concentration-dependent and demonstrated that the assay could be applied to its quantitation. Hence, it could also be used as a simple screening assay across multiple hosts (i.e. humans, birds, pigs) and multiple inuenza subtypes.
Current methods for epidemiological surveillance of inuenza in avian species rely on serological and egg yolk testing via virus isolation, reverse transcriptase-PCR, blocking enzyme-linked immunosorbent assay, agar gel immunodiffusion test and latex agglutination tests. [54] [55] [56] Comparatively, the NP-GFP agglutination assay offers a fast, simple and low-cost screening alternative for both serum (data not shown) and egg-derived IgY. Screening egg yolks has been found to be a more cost-effective method for poultry surveillance 57 and our data demonstrate the capability of our assay for testing puried IgY from egg yolk. Furthermore, recent strategies of vaccine development are based on eliciting NP antibodies. In a recent phase I clinical trial, modied vaccinia virus Ankara (MVA) vector expressing inuenza NP and matrix protein 1 (MVA-NP + M1) elicited a safe and immunogenic response in humans. 58 Here, the NP-GFP assay could be used to measure antibody titre post-vaccination and evaluate vaccine efficacies.
In conclusion, the NP-GFP assay is simple, rapid and versatile as it can be applied to the screening of drugs and antibodies targeting NP. The ligand-induced aggregation of NP can be accurately measured irrespective of its binding site. The assay requires minimal protein purication and offers sensitive quantitation even in protein mixtures, which is an advantage when monitoring the effect of biologics such as antibodies. Finally, with its exibility, we believe that NP-GFP aggregation assay will be a versatile tool for both inuenza research and the development of new NP-targeting antivirals.
